Eli Lilly: Still Much Room To Ride The Weight-Loss Wave
Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a ...
FDA Approves Weight-loss Drug Zepbound For Sleep Apnea – Will Insurance Cover This $1000-Per-Month Medication?
The U.S. Food and Drug Administration (FDA) recently approved Zepbound® (tirzepatide) as the first prescription medication for treating moderate-to-severe obstructive sleep apnea (OSA) in adults with ...
pharmaphorum22h
Lilly pledges £279m to UK for biotech hub and obesity plan
Eli Lilly has said it is prepared to invest £ ... plans to start a five-year real-world evidence study involving tirzepatide, the dual GIP/GLP-1 receptor agonist in the company's Mounjaro drug ...